8-K: Elevance Health Reports Strong 2023 Results and Sets Optimistic 2024 Outlook

Elevance Health reported a 9.3% increase in full-year operating revenue for 2023 and projects continued growth in 2024.

Summary

• Elevance Health's operating revenue for the fourth quarter of 2023 reached $42.5 billion, a 7% increase compared to the same period in 2022.
• Full-year 2023 operating revenue totaled $170.2 billion, marking a 9.3% increase from 2022.
• The company's GAAP diluted earnings per share (EPS) for the fourth quarter was $3.63, a 1.1% increase, while adjusted diluted EPS was $5.62, a 15.2% increase.
• For the full year, GAAP diluted EPS was $25.22, up 3.9%, and adjusted diluted EPS was $33.14, up 16.2%.
• Elevance Health projects a full-year 2024 GAAP diluted EPS of greater than $34.29 and adjusted diluted EPS of greater than $37.10.
• The company increased its quarterly dividend by 10.1% to $1.63 per share.
• Medical membership decreased by 1.2% year-over-year to 46.961 million, primarily due to Medicaid attrition.
• Operating cash flow for 2023 was $8.1 billion, 1.3 times GAAP net income.
• The company repurchased 5.8 million shares for $2.7 billion in 2023 and has $4.2 billion remaining in its share repurchase authorization.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, increased dividends, and optimistic future guidance. While there are some challenges, the overall tone is confident and forward-looking.

Positives

• Elevance Health demonstrated strong revenue growth in both the fourth quarter and full year of 2023.
• The company achieved significant growth in adjusted diluted EPS for both the quarter and the full year.
• The projected full-year 2024 EPS indicates continued positive financial performance.
• The increase in the quarterly dividend reflects confidence in the company's financial health.
• The company's operating cash flow is strong, at 1.3 times GAAP net income.
• Share repurchases demonstrate a commitment to returning value to shareholders.
• The benefit expense ratio improved, indicating better cost management.
• The Carelon segment showed strong revenue growth, particularly in CarelonRx.
• The company has a substantial remaining share repurchase authorization of $4.2 billion.

Negatives

• Medical membership decreased by 1.2% year-over-year, primarily due to Medicaid attrition.
• The operating expense ratio increased by 40 basis points for the full year, driven by business optimization charges.
• Operating gain in the Health Benefits segment declined by 2% in the fourth quarter due to investments in long-term growth.
• The company experienced a decrease in days in claims payable by 0.2 days compared to December 31, 2022.

Risks

• The company faces risks related to healthcare cost trends and utilization rates.
• Reduced enrollment could negatively impact revenue.
• The company's ability to secure and implement sufficient premium rates is a risk.
• Large-scale medical emergencies, such as pandemics, pose a risk.
• Changes in laws and regulations could impact the business.
• Cyber-attacks and data security breaches are a concern.
• Competitive pressures and the ability to adapt to industry changes are risks.
• Risks associated with Medicare and Medicaid programs exist.
• The company faces risks related to litigation, government investigations, and audits.
• The company's substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing is a risk.

Future Outlook

Elevance Health anticipates continued growth in 2024, projecting a full-year GAAP diluted EPS of greater than $34.29 and adjusted diluted EPS of greater than $37.10. The company expects flat to low-single digit growth in total operating revenue and greater than $8.1 billion in operating cash flow.

Management Comments

• Gail K. Boudreaux, President and Chief Executive Officer, stated that the company delivered another year of strong performance in 2023.
• Management expressed confidence in the 2024 outlook, supported by the company's business resilience and strategic execution.

Industry Context

This announcement reflects the ongoing trends in the healthcare industry, including the focus on customer experience, affordability, and the expansion of diversified services like pharmacy and digital health. The company's performance is being driven by premium revenue and growth in pharmacy product revenue, which is consistent with the broader industry's shift towards integrated healthcare solutions.

Comparison to Industry Standards

• Elevance Health's revenue growth of 9.3% for the full year is comparable to other large health insurers such as UnitedHealth Group, which reported a similar growth rate in their recent results.
• The company's adjusted EPS growth of 16.2% is strong and indicates effective cost management and operational efficiency, which is a key focus for companies in this sector.
• The projected 2024 EPS growth is also in line with industry expectations for continued growth in the healthcare sector.
• The company's focus on expanding its Carelon services is similar to other insurers who are diversifying their offerings to include pharmacy and other healthcare services, such as CVS Health and Cigna.
• The decrease in medical membership due to Medicaid attrition is a common trend across the industry as states resume eligibility redeterminations.

Stakeholder Impact

• Shareholders will benefit from increased dividends and share repurchases.
• Customers may experience improved services and affordability.
• Employees may see opportunities for growth and development.
• Suppliers and partners may benefit from the company's continued growth.

Next Steps

• Management will host a conference call and webcast to discuss the results and outlook.
• The company will continue to focus on customer experience, affordability, and investments in growth and innovation.
• Elevance Health will continue to optimize its foundation and scale its flywheel for sustained growth.

Key Dates

Keywords

Elevance Health, Healthcare, Health Insurance, Financial Results, Earnings, EPS, Revenue, Medical Membership, Carelon, Pharmacy, Dividends, Share Repurchase